Ok_老虎社区_美港股上老虎

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":603492383,"tweetId":"603492383","gmtCreate":1638436775897,"gmtModify":1638436776129,"author":{"id":3575418941864095,"idStr":"3575418941864095","authorId":3575418941864095,"authorIdStr":"3575418941864095","name":"weilhw","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":5,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Ok</p></body></html>","htmlText":"<html><head></head><body><p>Ok</p></body></html>","text":"Ok","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/603492383","repostId":1133804924,"repostType":4,"repost":{"id":"1133804924","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638436562,"share":"https://www.laohu8.com/m/news/1133804924?lang=zh_CN&edition=full","pubTime":"2021-12-02 17:16","market":"us","language":"en","title":"Glaxo and Vir Biotechnology stocks climbed in premarket trading<blockquote>葛兰素史克和Vir Biotechnology股票在盘前交易中上涨</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1133804924","media":"Tiger Newspress","summary":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effecti","content":"<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p><p><blockquote>早期测试显示，葛兰素史克和Vir Biotechnology的股票在盘前交易中上涨，因为葛兰素史克的新冠抗体药物对奥密克戎有效。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p><p><blockquote>葛兰素史克公司表示，该公司的Covid-19抗体治疗在早期测试中似乎对新的奥密克戎变种有效。</blockquote></p><p> Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p><p><blockquote>葛兰素史克周四在一份声明中表示，对该变种中发现的突变进行的实验室测试表明，该药物对病毒仍然有效。该制药商目前正在进行体外测试，以确认对所有奥密克戎突变组合的反应，并计划在年底前提供更新。</blockquote></p><p> Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p><p><blockquote>葛兰素史克对这种名为sotrovimab的药物发表评论之际，人们还不确定奥密克戎对现有药物和疫苗的防御能力的侵蚀程度。再生元制药公司本周早些时候表示，在早期证据表明其自身抗体可能效果较差后，该公司正在进行进一步测试。</blockquote></p><p> “Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p><p><blockquote>联合开发商Vir Biotechnology Inc.的首席执行官乔治·斯坎戈斯(George Scangos)表示：“Sotrovimab在设计时考虑到了一种变异病毒。”“这个假设已经被一次又一次地证实了。”</blockquote></p><p> The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p><p><blockquote>英国监管机构周四还批准了该药物的使用，此前该药物在试验中降低了轻度至中度Covid-19患者的住院和死亡风险。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaxo and Vir Biotechnology stocks climbed in premarket trading<blockquote>葛兰素史克和Vir Biotechnology股票在盘前交易中上涨</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxo and Vir Biotechnology stocks climbed in premarket trading<blockquote>葛兰素史克和Vir Biotechnology股票在盘前交易中上涨</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-02 17:16</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p><p><blockquote>早期测试显示，葛兰素史克和Vir Biotechnology的股票在盘前交易中上涨，因为葛兰素史克的新冠抗体药物对奥密克戎有效。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p><p><blockquote>葛兰素史克公司表示，该公司的Covid-19抗体治疗在早期测试中似乎对新的奥密克戎变种有效。</blockquote></p><p> Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p><p><blockquote>葛兰素史克周四在一份声明中表示，对该变种中发现的突变进行的实验室测试表明，该药物对病毒仍然有效。该制药商目前正在进行体外测试，以确认对所有奥密克戎突变组合的反应，并计划在年底前提供更新。</blockquote></p><p> Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p><p><blockquote>葛兰素史克对这种名为sotrovimab的药物发表评论之际，人们还不确定奥密克戎对现有药物和疫苗的防御能力的侵蚀程度。再生元制药公司本周早些时候表示，在早期证据表明其自身抗体可能效果较差后，该公司正在进行进一步测试。</blockquote></p><p> “Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p><p><blockquote>联合开发商Vir Biotechnology Inc.的首席执行官乔治·斯坎戈斯(George Scangos)表示：“Sotrovimab在设计时考虑到了一种变异病毒。”“这个假设已经被一次又一次地证实了。”</blockquote></p><p> The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p><p><blockquote>英国监管机构周四还批准了该药物的使用，此前该药物在试验中降低了轻度至中度Covid-19患者的住院和死亡风险。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GSK":"葛兰素史克","VIR":"Vir Biotechnology, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133804924","content_text":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effective on Omicron, early tests showed.\n\nGlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.\nLab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a statement Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.\nGlaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.\n“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”\nThe U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.","news_type":1,"symbols_score_info":{"GSK":0.9,"VIR":0.9}},"isVote":1,"tweetType":1,"viewCount":2743,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/603492383"}